Myeloma News and Research

RSS

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

The Department of Veterans Affairs (VA) has begun distributing disability benefits to Vietnam Veterans who qualify for compensation under recently liberalized rules for Agent Orange exposure.

2 Nov 2010

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

Oncolytics Biotech Inc. today announced that an abstract covering preclinical research with reovirus (REOLYSIN) is available on the European CanCer Organisation (ECCO). The research is scheduled to be presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16th - 19th 2010.

1 Nov 2010

ImmunoGen first quarter net loss increases to $12.9 million

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended September 30, 2010 - the first quarter of the Company's 2011 fiscal year (1QFY11).

29 Oct 2010

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene Corporation announced non-GAAP net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010.

28 Oct 2010

Reactivating three silenced molecules may provide new strategy to treat multiple myeloma

New research links three molecules to a critical tumor suppressor gene that is often turned off in multiple myeloma, a presently incurable cancer of the blood.

27 Oct 2010

New source of blood-derived biomarkers may help in cancer diagnosis

The future of cancer diagnosis may lie in just a few milliliters of blood, according to a research team led by Professor Arie Admon of the Technion-Israel Institute of Technology.

26 Oct 2010

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

19 Oct 2010

Scientists discover mechanism of anticancer drug to kill cancer cells

A potent drug derived from an evergreen tree may soon save the lives of some patients with the deadliest form of breast cancer. According to the National Cancer Institute, breast cancer will claim approximately 40,000 lives in the U.S. this year.

15 Oct 2010

Mesoblast broadens cancer indications for bone marrow transplant product

Australian regenerative medicine company Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that it is broadening the oncology applications of its "off-the-shelf" cell product for expansion of haematopoietic stem cells in patients with blood cancers. Building on the recent clinical success of Mesoblast’s proprietary cell product for expansion of cord blood, the Company will now address new markets where expansion of haematopoietic stem cells can make a meaningful impact on clinical outcomes, including diseases such as multiple myeloma.

13 Oct 2010

Humanitas Clinic treats first cancer patient using TrueBeam technology

A 54-year-old head & neck cancer patient has become the first person in Italy to be treated using a revolutionary new linear accelerator that can deliver radiotherapy twice as fast as conventional therapy machines. The Humanitas Clinic in Rozzano-Milan carried out the treatment last week, becoming only the third hospital in Europe to begin clinical treatments using TrueBeam from Varian Medical Systems.

13 Oct 2010

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

Scientists have found that a synthetic molecule they designed can block activation of a gene in liver cancer cells, halting a process that allows some of those cancer cells to survive chemotherapy.

13 Oct 2010

$Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer$

Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer

A surgical technique appears to offer quick and effective relief for debilitating spinal fractures often suffered by patients with metastatic cancer, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan.

11 Oct 2010

$Balloon kyphoplasty offers effective relief for debilitating spinal fractures suffered by metastatic cancer patients$

Balloon kyphoplasty offers effective relief for debilitating spinal fractures suffered by metastatic cancer patients

11 Oct 2010

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's lorvotuzumab mertansine (IMGN901) targeted anticancer compound at the 35th European Society for Medical Oncology (ESMO) Conference being held in Milan, Italy, October 8-12, 2010.

11 Oct 2010

Phase-II clinical trial of MLN8237 drug shows promising results for treating ovarian cancer

A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported.

11 Oct 2010

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

Onyx Pharmaceuticals, Inc. today announced that it will delay its New Drug Application (NDA) filing for carfilzomib based on a recent meeting with the Chemistry, Manufacturing and Controls (CMC) review division of the U.S. Food and Drug Administration (FDA).

7 Oct 2010

Myeloma News and Research

Immunomedics product candidates, technologies receive recognition from QTDP program

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

ImmunoGen first quarter net loss increases to $12.9 million

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Reactivating three silenced molecules may provide new strategy to treat multiple myeloma

New source of blood-derived biomarkers may help in cancer diagnosis

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Scientists discover mechanism of anticancer drug to kill cancer cells

Mesoblast broadens cancer indications for bone marrow transplant product

Humanitas Clinic treats first cancer patient using TrueBeam technology

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

Balloon kyphoplasty relieves painful spine fractures in patients with metastatic cancer

Balloon kyphoplasty offers effective relief for debilitating spinal fractures suffered by metastatic cancer patients

Promising clinical data of ImmunoGen's lorvotuzumab mertansine to be presented at ESMO conference

Phase-II clinical trial of MLN8237 drug shows promising results for treating ovarian cancer

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

Otsuka opens Canadian operations

Study shows hypomethylation increases through progression of multiple myeloma

Report finds development of multiple myeloma is tied to 'hypomethylation'

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News